Positivity for IL-13Rα2 was associated with a 7.191-fold increased risk of mortality in osteosarcoma patients (95% CI: 2.063–25.067; p = 0.002) and a 6.616-fold increased likelihood of tumor relapse or patient death (95% CI: 1.909–19.883; p = 0.002) (Table 3). Here, IL13RA2 is linked to neoplasm.